CeriXMedical Esthetics ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  3.1% 1.1% 0.9% 4.9% 9.9%  
Credit score (0-100)  60 90 94 51 28  
Credit rating  BBB A A BBB BB  
Credit limit (kDKK)  0.0 231.9 665.9 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  8,203 6,741 6,227 3,064 594  
EBITDA  2,178 1,957 2,852 -921 -4,365  
EBIT  1,530 1,316 2,665 -1,083 -4,612  
Pre-tax profit (PTP)  1,769.7 1,785.6 2,922.3 -743.9 -4,686.2  
Net earnings  1,375.8 1,387.6 2,284.4 -597.0 -3,693.6  
Pre-tax profit without non-rec. items  1,770 1,786 2,922 -744 -4,686  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  989 776 1,249 1,088 861  
Shareholders equity total  2,542 3,929 6,214 5,455 1,762  
Interest-bearing liabilities  3,483 0.0 107 750 5,071  
Balance sheet total (assets)  11,762 8,754 10,754 10,308 10,025  

Net Debt  3,314 -1,782 -15.5 317 4,364  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  8,203 6,741 6,227 3,064 594  
Gross profit growth  54.9% -17.8% -7.6% -50.8% -80.6%  
Employees  11 10 6 8 9  
Employee growth %  120.0% -9.1% -40.0% 33.3% 12.5%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  11,762 8,754 10,754 10,308 10,025  
Balance sheet change%  93.1% -25.6% 22.8% -4.1% -2.7%  
Added value  2,178.4 1,957.2 2,852.4 -895.8 -4,364.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -567 -854 286 -323 -474  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 -1.0 -2.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  18.7% 19.5% 42.8% -35.3% -776.1%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  20.1% 17.7% 30.1% -6.8% -42.2%  
ROI %  45.1% 33.9% 50.8% -10.6% -64.9%  
ROE %  74.2% 42.9% 45.0% -10.2% -102.4%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  21.6% 45.0% 58.0% 53.3% 17.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  152.1% -91.1% -0.5% -34.4% -100.0%  
Gearing %  137.0% 0.0% 1.7% 13.7% 287.9%  
Net interest  0 0 0 0 0  
Financing costs %  1.3% 1.6% 25.5% 6.5% 13.6%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  1.1 1.8 2.4 1.9 1.1  
Current Ratio  1.2 1.8 2.6 2.1 1.1  
Cash and cash equivalent  169.4 1,782.3 122.1 432.5 707.1  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,711.9 3,629.3 5,780.2 4,801.3 1,159.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  198 196 475 -112 -485  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  198 196 475 -115 -485  
EBIT / employee  139 132 444 -135 -512  
Net earnings / employee  125 139 381 -75 -410